Lundbeck has another chance to crow this week, now that its once-monthly version of Abilify has FDA approval. The agency nod comes fast on the heels of another, for the Danish drugmaker's alcohol addiction drug Selincro. This double victory opens the way for Lundbeck to transform turnaround promises into actual sales.
U.S. regulators handed Otsuka Pharmaceutical and Lundbeck some good news today, stamping an approval on the two drugmakers' once-monthly version of the big-selling schizophrenia drug Abilify.
Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to...
The market for schizophrenia drugs will shrink over the next couple of years, Decision Resources finds, but will bounce back after that, thanks to new drugs that can be priced at a premium to older treatments.
Lundbeck and its partner Otsuka have put their bid for an approval of their long-acting version of the antipsychotic drug Abilify back on the regulatory track. The partners on aripiprazole say that the FDA has accepted their resubmission for the treatment and set a PDUFA deadline for the end of February in 2013.
Generics have hit the antidepressant market hard. With patents on some key drugs either expired or near expiration, analysts figure the $12.3 billion field will lose more than $2 billion in value by 2021. Finding new drugs could turn the numbers around, but these days, fewer drugmakers are even looking.
Now that Plavix and Lipitor are down for the count, AstraZeneca's Nexium is the reigning heavyweight drug champion. According to Drugs.com, the stomach drug outsold all other branded drugs during the second quarter, with $1.38 billion in revenues. But Nexium's dominance could be short-lived.
Lundbeck's CFO Anders Gotzsche emphasized the prospects of drugs such as Selincro for alcohol dependence, the experimental antidepressant Lu AA21004 in late-stage development and a long-lasting formulation of Abilify.
Bristol-Myers Squibb's ( $BMY ) earnings didn't reach the Wall Street goalposts, partly because of higher costs, some of them attributed to U.S. healthcare reforms. Sales of its flagship drug,...
Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,